New Menopause Treatments 2026: What’s New, Who It’s For, and What It Costs
By The HRT Index Editorial Team · Last verified:
The HRT Index is an independent comparison resource for HRT telehealth providers. Some links below are partner links — if you start care through one, we may earn a commission at no extra cost to you. Partner status never changes the facts we verify, the safety cautions we include, or who we’d point you to. This page is education, not medical advice.
Here’s the honest version. When it comes to new menopause treatments 2026, the biggest news isn’t one magic cure. It’s a bigger, better menu — plus a major shift in how doctors talk about it.
Two things changed. First, there are now two non-hormonal prescription pills that calm hot flashes from inside the brain: Veozah (approved in 2023) and Lynkuet (brand-new, approved October 2025). Second, on February 12, 2026, the FDA removed its strongest warnings — about heart disease, breast cancer, and dementia — from the “boxed warning” on the first six FDA-approved menopause hormone therapy products.
Which path is right for you comes down to three things: whether you can take hormones, which symptom bothers you most, and your insurance. Every price and fact below is checked against primary sources — the FDA, the drug labels, and each provider — and dated so you can see how fresh it is.
| What’s new (or newly important) in 2026 | What actually changed | Best for | Hormone? | The catch |
|---|---|---|---|---|
| FDA warning change | Heart, breast-cancer, and dementia language removed from the boxed warning on the first 6 hormone products (Feb 12, 2026) | Anyone scared off HRT by old warnings | — | Only 6 products so far. Risk isn’t zero. |
| FDA-approved hormone therapy (HRT) | Not new, but discussed more openly now | Hot flashes, night sweats, vaginal symptoms, bone health | Yes | Needs an individual risk check; not for everyone |
| Lynkuet (elinzanetant) | New FDA approval, Oct 24, 2025 | Moderate-to-severe hot flashes, if you can’t or won’t take hormones | No | ~$625/mo without insurance; liver tests |
| Veozah (fezolinetant) | Approved 2023, now well established | Same as above | No | Carries a boxed liver warning; more lab checks |
| Vaginal / GSM treatments | Newly emphasized as a separate path | Dryness, painful sex, urinary symptoms | Local or non-hormone | The “new pills” don’t fix these symptoms |
| Older non-hormonal meds | Still useful, often cheap | Hot flashes plus mood/sleep, or tight budgets | No | Off-label; side effects vary |
| Menopause telehealth | Easier online access | People ready to talk to a clinician | Depends | Severe/complex cases may need in-person care |
Sources: FDA, Bayer, Astellas, and provider pages — see Sources at the end. Prices verified .
Not sure which lane is yours?
Take our free 60-second Menopause Treatment Path quiz. You’ll get a plain-English starting point to bring to a clinician — it takes about a minute.
Find my treatment path →What are the new non-hormonal menopause pills in 2026?
When your estrogen falls during menopause, a cluster of brain cells (researchers call them KNDy neurons) gets overactive. Those cells help control your body temperature. When they go haywire, you get a hot flash — that sudden wave of heat, flushing, and sweat. These two pills work by blocking the signals that fire those cells. No estrogen involved.
That matters for a lot of women. If hormones aren’t a fit for you — because of your medical history or simply your preference — these give you a real prescription option to ask a clinician about. They target the cause of hot flashes without using estrogen.
Lynkuet (elinzanetant) — the newest option
Bayer’s pill won FDA approval on October 24, 2025, and reached U.S. pharmacies in November 2025. It’s the first “dual” blocker — it hits two brain targets (NK1 and NK3) instead of one.
Dose: 120 mg (two 60 mg capsules) once a day at bedtime.In Bayer’s OASIS trials, relief often began within about a week, and most women cut their moderate-to-severe hot flashes by at least half within three months. Many also reported better sleep.
Veozah (fezolinetant) — the established option
Astellas got FDA approval in May 2023, making it the first pill of this kind. It blocks one target (NK3) and is taken as a 45 mg pill once a day.
By 2026 it has a longer track record and plenty of real-world use — if you want the option with the most accumulated data, Veozah has it.
What these pills do NOT treat
Veozah and Lynkuet are for hot flashes and night sweats only. They do nottreat vaginal dryness, painful sex, or urinary symptoms (that’s GSM — more below), they’re not a bone-loss treatment, and they’re not a fix for weight, mood, or libido on their own. If those are your main concerns, a different path fits better.
The catch nobody puts in the headline
“New” does not mean “gentle” or “cheap.” Both pills can raise your liver enzymes, so both require liver blood tests. And without insurance, both run around $625 a month.
With a manufacturer copay card and commercial insurance, many people pay far less — more on exact prices below. And the monitoring is manageable. The next section shows you the real differences so you can choose with your clinician.
Want a non-hormonal starting point?Use the quiz and pick the “non-hormonal” path. We’ll build you a short list of questions to ask about Veozah, Lynkuet, and other options.
Build my non-hormonal question list →Lynkuet vs Veozah: how the two new pills really compare
| Lynkuet (elinzanetant) | Veozah (fezolinetant) | |
|---|---|---|
| FDA approval | Oct 24, 2025 | May 12, 2023 |
| Maker | Bayer | Astellas |
| How it works | Blocks two brain targets (NK1 + NK3) | Blocks one (NK3) |
| Hormone? | No | No |
| Dose | 120 mg (two 60 mg capsules) at bedtime | 45 mg, once daily |
| How fast it works | Relief often in ~7 days; most cut hot flashes by half within 3 months | Significant relief within weeks |
| Liver blood tests | Baseline, then at 3 months | Baseline, monthly for 3 months, then at 6 and 9 months |
| Price (no insurance) | ~$625/month | ~$550–$690/month |
| Price with savings card* | As low as $25/month | $0 first month, then ~$30/month |
| Extra perk | Reported sleep benefit | Longer real-world track record |
| Boxed liver warning? | No (liver caution only) | Yes — rare but serious liver injury |
| Other cautions | Drowsiness/dizziness (~12% vs ~3% on placebo); no use in pregnancy; caution if seizure history; avoid grapefruit | Liver risk; avoid certain interacting meds; not for known liver problems; avoid grapefruit |
*Savings cards require commercial insurance and are not valid for Medicare or Medicaid. Sources: Lynkuet prescribing information (DailyMed); FDA Veozah liver-safety communication; Veozah savings. Prices verified June 8, 2026.
Our read (editorial opinion, based on verified facts)
If your main goals are fewer appointments and you also struggle with sleep, Lynkuet’s lighter monitoring and sleep benefit are appealing. If you want the option with the longest history, that’s Veozah. Cost is basically a wash. Neither is a hormone — and neither replaces a clinician’s check of your history.
One expert summed up the bigger picture well. Dr. James A. Simon, a clinical professor of OB-GYN, called the newest approval “a significant advance for women’s health.” More choices, finally.
What side effects and lab tests come with Lynkuet and Veozah?
- Liver tests. Lynkuet: a blood test before you start and again at 3 months. Veozah: before you start, monthly for the first 3 months, then at months 6 and 9. Stop and call your clinician if you notice yellow skin or eyes, dark urine, pale stools, nausea, itching, or unusual tiredness.
- Drowsiness/dizziness. Reported in about 12% of Lynkuet users (vs about 3% on placebo). Don’t drive until you know how it affects you.
- Pregnancy. Neither is for use in pregnancy.
- Seizure history. Tell your clinician — relevant for Lynkuet.
- Grapefruit. Avoid grapefruit and grapefruit juice with these medications.
This is the kind of detail a clinician will walk through with you. It’s manageable for most people — it just isn’t “set it and forget it.”
What did the FDA change about hormone therapy in 2026?
This is the change behind all those “HRT is back” headlines. Here’s what really happened — and what didn’t.
First, a quick definition. A boxed warning(you may know it as a “black box warning”) is the most serious alert the FDA can put on a drug. For 23 years, estrogen products carried one.
The short timeline:
- 2002–2004: A big study called the Women’s Health Initiative (WHI) linked hormone therapy to higher risks. The strong warnings followed in 2003.
- 2025: After reviewing decades of newer evidence, an FDA expert panel and the agency concluded those blanket warnings scared women away from a treatment that helps many of them.
- November 10, 2025: The FDA and HHS announced they’d start removing the warnings.
- February 12, 2026: The FDA approved the first six label changes.
| ✅ Removed from the boxed warning | ⚠️ Kept / still true |
|---|---|
| Heart-disease risk statement | Uterine (endometrial) cancer warning stays for estrogen-alone systemic products (if you have a uterus) |
| Breast-cancer risk statement | Heart and breast-cancer information is still on the label — just not in the box |
| Probable-dementia risk statement | Change covers the first 6 products only — 29 companies are still submitting |
| The old “lowest dose for the shortest time” instruction was dropped from the updated boxed warning | Your risk still depends on age, the product, the dose, and your history |
| Added: a note that starting therapy may be reasonable for women under 60 or within 10 years of menopause | HRT is still a prescription decision that needs an individual review |
Source: FDA press release, Feb 12, 2026.
Which six HRT products changed first?
| Product | What it is | Category |
|---|---|---|
| Prometrium | Progesterone capsules | Progestogen-alone (for women using systemic estrogen who have a uterus) |
| Divigel | Estradiol gel | Systemic estrogen-alone |
| Cenestin | Synthetic conjugated estrogens, A (tablets) | Systemic estrogen-alone |
| Enjuvia | Synthetic conjugated estrogens, B (tablets) | Systemic estrogen-alone |
| Estring | Estradiol vaginal ring | Topical vaginal estrogen |
| Bijuva | Estradiol + progesterone capsules | Systemic combination |
Source: FDA, Feb 12, 2026.
So is HRT “safe now”?
Not automatically.The FDA’s view is that the old blanket warnings overstated the risk for most women who start hormone therapy under 60 or within 10 years of menopause — and the agency points to randomized studies showing that group tends to see lower overall death and fracture rates. But the risk isn’t zero, it varies by your situation, and it remains a prescription decision.
The honest takeaway: the conversation got more nuanced, not more automatic. For many healthy women with hot flashes in that under-60 window, the door is now more open than it’s been in two decades. It just isn’t a green light for everyone.
Full breakdown: Menopause Hormone Therapy Safety Update 2026 · 2026 HRT Label Changes Explained · HRT Breast Cancer Risk 2026
Want the FDA-approved-only route?Take the quiz and choose “FDA-approved options only.” We’ll point you toward the care paths worth comparing.
See FDA-approved options →Which treatment path fits your main symptom?
If your main problem is hot flashes or night sweats
These are what doctors call vasomotor symptoms (VMS). You have the most options here.
| If this is you… | Ask about… | Why |
|---|---|---|
| Healthy, under 60 or within 10 years of menopause, no major red flags | FDA-approved systemic hormone therapy | Still the most effective option for hot flashes for many good candidates |
| Can't or won't take hormones | Veozah or Lynkuet | Non-hormonal pills aimed right at the cause |
| Hot flashes mostly wreck your sleep | HRT, Lynkuet, Veozah, or gabapentin | Lynkuet may help sleep too; some meds target nighttime symptoms |
| Cost is your deciding factor | Generic hormone therapy or older non-hormonal pills | Often the cheapest, but fit and safety come first |
If your main problem is vaginal dryness, painful sex, or urinary symptoms
This is GSM — genitourinary syndrome of menopause. This is important: the new hot-flash pills do not treat these symptoms. For GSM, the conversation is usually about more targeted, often lower-dose options:
- Low-dose vaginal estrogen — works mainly where you apply it (“local”), with little reaching the rest of the body.
- Vaginal DHEA (prasterone) — a non-estrogen insert.
- Ospemifene — a pill for painful sex.
- Moisturizers and lubricants — simple, helpful add-ons.
- Pelvic floor therapy — when appropriate.
If your symptoms are mostly vaginal or urinary, you may not need whole-body treatment at all. See our guide to vaginal estrogen and GSM treatment.
If your main problem is brain fog, sleep, mood, weight, or libido
If your symptoms are mostly vaginal or urinary, don’t compare full-body programs yet. Start with the GSM path in the quiz so you walk in asking the right questions.
Start the GSM path →What older non-hormonal treatments still matter in 2026?
The “new pill” headlines can make these feel outdated. They’re not. They’re often cheap and effective.
- Low-dose paroxetine (Brisdelle) — the one antidepressant the FDA specifically approved for hot flashes. Other SSRIs/SNRIs are used off-label.
- Gabapentin — a nerve medication that can help nighttime hot flashes.
- Clonidine — a blood-pressure medication; side effects limit it for some.
- Oxybutynin — can reduce hot flashes, though older adults should weigh the trade-offs with a clinician.
Many of these are generics that are often lower-cost than the brand-name neurokinin pills. If budget is your top concern, they’re worth raising. See our non-hormonal menopause treatment options guide.
What menopause treatments should you be skeptical of?
Compounded means a pharmacy mixes a product to order. Compounded hormones are not FDA-approved as specific finished products— the FDA hasn’t reviewed that exact formula for safety, strength, or how well it works.
“Bioidentical”is a marketing word, not an FDA category. Some FDA-approved hormones happen to be bioidentical. But “bioidentical” on its own does notmean “FDA-approved,” and the two are not the same thing.
Real-world example: Oestra (Inner Balance)
Oestra is a popular estradiol-and-progesterone vaginal cream priced at $199/month for the first six months, then $99.50/month. The company markets it as delivering whole-body (“systemic”) results. It may suit some people — but it’s a compounded product, mixed to order in a licensed pharmacy and not FDA-approved as a finished drug,it doesn’t bill insurance, and its money-back guarantee comes with conditions worth reading before you commit. If you have a uterus, ask a clinician directly how a compounded cream protects your uterine lining, because compounded regimens are not the same as the FDA-approved ones studied for that purpose. Treat the company’s outcome claims as marketing, not independent proof.
When might compounded make sense? In specific cases — an allergy to an ingredient in the standard product, a dose or form that isn’t sold commercially, or a documented clinical need. Compare compounded HRT providers.
As for supplements and “natural hormone” creams: the FDA says it doesn’t know whether many herbal or “natural” products are safe or helpful, and it warns about false claims. Use them as add-ons if you like — not as a replacement for treatment that’s actually been studied.
How much do new menopause treatments cost in 2026?
Don’t compare sticker prices alone. Compare the whole path.
| Path | What it tends to cost | What to check |
|---|---|---|
| Generic FDA-approved HRT | Often $10–$30/mo with insurance (varies by pharmacy) | Pharmacy price, coverage, patch supply |
| Midi Health | Self-pay $250 first visit, $150 follow-ups; ~$50 avg out-of-pocket with PPO insurance | In-network status, your state |
| Sesame menopause subscription | $99/month subscription (medication billed separately) | Cash-pay only; HSA/FSA accepted |
| Winona | From $39/mo (progesterone) to $149/mo (estradiol patch) | FDA-approved vs. compounded product |
| Hers | Estradiol patch kits from $134/month | State availability, your plan |
| Lynkuet | ~$625/mo list; as low as $25/mo with savings card (commercial insurance) | Copay-card eligibility |
| Veozah | ~$550–$690/mo list; $0 first month then ~$30/mo with savings card (commercial insurance) | Prior authorization, liver labs |
Prices verified . Manufacturer savings cards require commercial insurance and are not valid for Medicare or Medicaid; uninsured patients may qualify for patient-assistance programs.
A quick, important note on testosterone: some women use low-dose testosterone off-label for libido. In the U.S., testosterone is a Schedule III controlled substance, so it always requires a prescription and proper clinical oversight — there’s no shortcut around that.
Want to know what’s realistic for your situation? Check coverage and pricing with a menopause-focused clinician before you commit.
Check Midi coverage and pricing in your state →Where can you get new menopause treatments online in 2026?
| Provider | Price (verified June 8, 2026) | Insurance | Labs / medication | FDA-approved or compounded | Heads-up |
|---|---|---|---|---|---|
| Midi Health | $250 first visit, $150 follow-ups self-pay; ~$50 avg with PPO | Bills most PPOs; no Medicaid/Medi-Cal; Medicare self-pay only | Labs ordered as needed; prescribes FDA-approved HRT + non-hormonal (e.g., Veozah) | FDA-approved meds | Not the cheapest flat price; billing can vary |
| Sesame | $99/mo subscription | Cash-pay (HSA/FSA); no insurance billing | Visits + labs if ordered; medication billed separately | Prescribes FDA-approved HRT + non-hormonal | Confirm current price at signup |
| Winona | $39/mo (progesterone), $54/mo (tablets), $89/mo (combo cream), $149/mo (patch) | Cash-pay (HSA/FSA); no insurance | Medication only; no required lab tests | FDA-approved patch/tablets/progesterone + compounded creams | Confirm which you’re prescribed |
| Hers | Estradiol patch kits from $134/mo | Cash-pay | Pill, patch, or cream | FDA-approved generics | Not in all 50 states yet |
Our pick for most insured readers: Midi Health
If you want a menopause-focused clinician who takes insurance, Midi Healthis the cleanest fit for this page. It’s available in all 50 states, is in-network with most PPO plans, and prescribes the full range — FDA-approved hormone therapy in every form (patch, gel, pill, cream) and non-hormonal options like Veozah. Visits are run by clinicians who specialize in menopause and perimenopause.
The honest trade-off: Midi does not have the lowest flat sticker price. Self-pay is $250 for a first visit, and a few patients report insurance billing surprises. So if a rock-bottom, predictable cash price is your single most important factor, Winona or Sesame will be easier to budget. But for most insured readers, Midi skips the flat-fee model precisely because it bills insurance and staffs specialists. With in-network coverage, most patients pay around $50 a visit, and you get the new FDA-approved options prescribed with real clinical oversight.
Check Midi availability in your state →If you want a flat cash price with labs included: Sesame
Sesame runs a menopause subscription at $99/monththat includes video visits and lab work if your provider orders it, with access to both hormonal and non-hormonal prescriptions. You pay for any medication separately at your pharmacy. It doesn’t bill insurance (cash-pay), but you can use HSA/FSA funds.
See Sesame’s menopause visit options →If you want low-friction, no-blood-test convenience: Winona
Winona uses a cash-pay model with no membership fee and no routine blood test required. Pricing runs from $39/month for progesterone capsules and $54/month for estrogen tablets, to $89/month for its popular estrogen-plus-progesterone cream and $149/month for the estradiol patch. One thing to know:Winona offers both FDA-approved products and compounded formulations. If you want FDA-approved therapy specifically, confirm which product you’re being prescribed. (Winona does not prescribe testosterone.)
Read the full Winona review →Who should skip telehealth for now?
If you have unexplained vaginal bleeding, an active or complex cancer history, or severe symptoms with an unclear cause, start with an in-person or specialist visit instead.
What should make you slow down before choosing a treatment?
A trustworthy guide tells you when not to take the easy path. If any of these apply, treat your quiz result as a list of questions — not a treatment plan — and start with a clinician who can review your full history:
- Unexplained or postmenopausal vaginal bleeding
- A history of certain cancers, or active cancer treatment
- Past blood clots, stroke, or heart attack
- Liver disease
- A chance you could be pregnant
- A history of seizures (relevant for the newer pills)
- Complex medication interactions
What should you ask your clinician before starting a 2026 menopause treatment?
Save this list or screenshot it before your visit. It turns a rushed appointment into a real plan.
- Is my main issue hot flashes, vaginal/urinary symptoms, sleep, mood, or a mix?
- Am I a reasonable candidate for FDA-approved hormone therapy?
- Am I under 60 or within 10 years of menopause?
- Do I have a uterus — and if so, how are we protecting the uterine lining?
- Would a patch or gel be safer for me than a pill?
- Should I consider a non-hormonal option like Veozah, Lynkuet, or paroxetine?
- Do I need liver blood tests before or during a non-hormonal pill?
- What side effects should make me stop and call you?
- How soon should I feel better?
- What happens if my medication is out of stock?
- What’s the real first-90-day cost — visits, labs, medication, and follow-ups?
- Is what you’re prescribing FDA-approved, compounded, or off-label?
- How often will we recheck and adjust?
What’s the best menopause treatment in 2026?
| If you’re really asking… | Your best next question |
|---|---|
| “Can I take HRT now?” | Am I a good candidate based on my age, timing, uterus status, and history? |
| “What’s the new pill?” | Am I a candidate for Lynkuet or Veozah, and what monitoring is involved? |
| “I have vaginal dryness or pain” | Do I need local vaginal treatment instead of whole-body therapy? |
| “I’m scared of hormones” | Is non-hormonal a better fit — or am I reacting to outdated warnings? |
| “I want online care” | Which telehealth option fits my insurance, state, and symptoms? |
When you’re ready to move from reading to a real plan, the fastest first step is matching your symptoms to a lane, then bringing that to a clinician.
See your starting point in about a minute
Our free Menopause Treatment Path quiz turns your answers into a short, clinician-ready plan.
Find my treatment path →No email required. No diagnosis. No pressure.
What we actually verified
FDA hormone-therapy label change — the Feb 12, 2026 boxed-warning removal, the six named products, and what stayed (FDA press release).
Lynkuet and Veozah — approval dates, dosing, how they work, liver monitoring, side effects, and warnings (Bayer and Astellas prescribing information; FDA liver-safety communication).
Current pricing — Lynkuet (~$625/mo list; ~$25 with savings card), Veozah ($0 first month, then ~$30 with savings card), and provider costs (manufacturer pages, GoodRx, and each provider’s own site).
Provider facts — Midi, Sesame, Winona, and Hers pricing, insurance, and state availability (each provider’s official pages and recent reporting).
Last verified: · By: The HRT Index Editorial Team · Re-check schedule: Quarterly, and sooner when the FDA issues news.
Still deciding?
You came here to find out what’s real in new menopause treatments 2026— and now you know: two non-hormonal pills, a major FDA warning change, and more ways than ever to get care. The honest catch is that “best” depends on you. So let’s make it personal.
Still not sure which HRT program is right for you? Take our free 60-second matching quiz.
Find my treatment path →Related reading: Menopause HRT Safety Update 2026 · 2026 HRT Label Changes · HRT Breast Cancer Risk 2026 · Compare HRT Providers
Frequently asked questions about new menopause treatments in 2026
Answers based on FDA primary sources, Bayer, Astellas, and major medical societies — verified . For your personal situation, talk to a licensed clinician.
- What is the newest menopause treatment in 2026?
- The newest FDA-approved prescription is Lynkuet (elinzanetant), approved in October 2025 for moderate-to-severe hot flashes due to menopause. The bigger 2026 story is the combination of Lynkuet, Veozah, the FDA's hormone-therapy warning change, and easier menopause telehealth access.
- What is the new pill for menopause hot flashes?
- The two newer pills are Veozah (fezolinetant), approved in 2023, and Lynkuet (elinzanetant), approved in 2025. Both are non-hormonal and work by calming brain cells that trigger hot flashes, rather than using estrogen.
- Is HRT safe now?
- Not automatically. The FDA's 2026 label changes make the risk conversation more nuanced, especially for healthy women under 60 or within 10 years of menopause, but hormone therapy still needs an individual risk review and isn't right for everyone.
- Did the FDA remove the black box warning from HRT?
- The FDA removed the heart-disease, breast-cancer, and dementia statements from the boxed warning on the first six hormone therapy products in February 2026. It kept the uterine (endometrial) cancer warning for estrogen-alone systemic products, and many other products still carry the older label.
- Which six HRT products had their labels changed first?
- Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. They span all four categories of hormone therapy: systemic combination, systemic estrogen-alone, systemic progestogen-alone, and topical vaginal estrogen.
- Is Veozah better than HRT?
- They are different tools. Veozah is non-hormonal and useful for people who cannot or will not take hormones, but it has liver-monitoring requirements and only treats hot flashes — not vaginal or urinary symptoms. Hormone therapy treats a wider range of symptoms for appropriate candidates.
- Is Lynkuet better than Veozah?
- There is no simple public head-to-head winner. They are different non-hormonal pills with different monitoring and side-effect profiles. Veozah carries a boxed liver warning and needs more frequent early labs, while Lynkuet's monitoring is lighter and it may help sleep. The choice belongs in a clinician discussion.
- Can I use HRT if I still have my uterus?
- Possibly, but if you take systemic estrogen and have a uterus, you will usually need progesterone or a progestogen to protect the uterine lining. The FDA specifically kept the uterine-cancer warning for estrogen-alone systemic products for this reason.
- Are compounded “bioidentical” hormones FDA-approved?
- No. The FDA says many marketed “bioidentical” hormones are compounded drugs, which are not FDA-approved, and it has no evidence they are safer or more effective than FDA-approved hormone therapy.
- Can I get menopause treatment online?
- Yes, when a licensed clinician decides telehealth is appropriate for you. Providers like Midi, Sesame, Winona, and Hers offer online menopause care, though severe or complex cases may need in-person care.
- What is the cheapest menopause treatment?
- There is no single cheapest option, because cost includes visits, labs, medication, and follow-ups. Generic hormone therapy or older generic non-hormonal pills are often lowest-cost, while brand-name pills like Lynkuet and Veozah depend heavily on insurance and savings cards.
- Do I need lab tests before menopause treatment?
- Sometimes. Menopause is often diagnosed from symptoms, so tests are not always needed to diagnose it, but a clinician may order labs depending on your symptoms, risks, and treatment plan, and the non-hormonal pills require liver blood tests.
- What if I have a history of breast cancer?
- Don’t rely on a generic internet answer for this. Start with an oncology-informed clinician or menopause specialist, because both hormonal and non-hormonal options have to be tailored to your specific history.
Sources
- FDA — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (press release, Feb 12, 2026)
- HHS — FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products (Nov 10, 2025)
- Pharmacy Times / Urology Times / Contemporary OB/GYN — the six named products and four categories
- Bayer — Lynkuet (elinzanetant) FDA approval (Oct 24, 2025)
- DailyMed — Lynkuet (elinzanetant) prescribing information (dosing, liver monitoring, side effects, warnings)
- CBS News / Reuters / manufacturer — Lynkuet list price (~$625/mo) and savings card (~$25/mo)
- FDA — Veozah (fezolinetant) approval (May 2023) and Drug Safety Communication: boxed warning for serious liver injury (Dec 16, 2024)
- Veozah (Astellas) — savings program ($0 first month, ~$30/month, commercial insurance only)
- Contemporary OB/GYN — Dr. James A. Simon comment on elinzanetant approval
- FDA — Menopause (compounded vs. FDA-approved; reasons some women should not take hormone therapy)
- Mayo Clinic — menopause treatment options (vaginal estrogen, prasterone, ospemifene, SSRIs/SNRIs, gabapentin, clonidine, oxybutynin)
- Midi Health — pricing/insurance and cost pages, testimonials, state availability (joinmidi.com)
- Sesame — menopause subscription details (sesamecare.com)
- Winona — product pricing and model: cash-pay; FDA-approved and compounded options; no testosterone (bywinona.com)
- Reuters — Hers menopause launch and estradiol patch kits from $134/month
- Inner Balance / Consumer Affairs — Oestra pricing ($199/mo for 6 months, then $99.50) and compounded status
- eCFR (21 CFR 1308.13) — testosterone as a Schedule III controlled substance
About this page
Written by: The HRT Index Editorial Team — The HRT Index, an independent comparison resource for HRT telehealth providers.
Review status: Independent editorial research. Not medical advice. Any decision about menopause treatment should be made with a licensed clinician.
Last updated: · Last verified: